Kristie L. Kahl


Two Years Post-operative ADT Plus Radiotherapy Improves MFS, Time to Salvage Therapy in Prostate Cancer

September 12th 2022

The addition of 24 months of androgen deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved time to salvage therapy in patients with prostate cancer.

Tucatinib Plus Trastuzumab Elicits Responses in Crossover Cohort in HER2+ mCRC

September 12th 2022

Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.

Cabozantinib Improves PFS Outcomes With Nivolumab, Ipilimumab in Advanced RCC

September 12th 2022

The triplet regimen of cabozantinib plus standard-of-care nivolumab and ipilimumab reduced the risk of disease progression or death by 27% vs placebo in patients with advanced renal cell carcinoma.

Neoadjuvant Cemiplimab Elicits Encouraging Pathologic Complete Response in CSCC

September 12th 2022

Cemiplimab produced pathologic complete responses as a neoadjuvant treatment in more than half of patients with resectable, stage II to IV cutaneous squamous cell carcinoma.

Adjuvant Nivolumab Plus Ipilimumab Fails to Improve DFS in Localized, High-Risk RCC

September 11th 2022

The combination of adjuvant nivolumab and ipilimumab did not elicit a significant disease-free survival benefit vs placebo in patients with localized, renal cell carcinoma at high risk for relapse after nephrectomy.

Tremelimumab Plus Durvalumab/Chemo Maintains OS Benefit in Metastatic NSCLC

September 11th 2022

The frontline combination of tremelimumab plus durvalumab and chemotherapy generated a long-term overall survival benefit in patients with metastatic non–small cell lung cancer.

Abemaciclib Plus Trastuzumab Results in Numerical OS Improvement Vs SOC in HR+, HER2+ Advanced Breast Cancer

September 10th 2022

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC

September 10th 2022

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

LEAP-002 Trial Misses Primary End Points, But Data Support Role of Lenvatinib Monotherapy as SOC in Frontline HCC

September 10th 2022

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer

September 9th 2022

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

September 9th 2022

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Dostarlimab Demonstrates Promising Response Rates in Advanced, Recurrent Endometrial Cancer

June 8th 2022

Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.

Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors

June 7th 2022

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

Adagrasib Elicits Deep and Durable Responses in Pretreated KRAS G12C–Mutant NSCLC

June 3rd 2022

Adagrasib led to early onset and deep responses translating to encouraging survival as a single agent in previously treated patients with KRAS G12C–mutated non–small cell lung cancer, according to results from cohort A of the phase 1/2 KRYSTAL-1 trial.

Nimotuzumab Plus Gemcitabine Improves Survival in KRAS Wild-Type Pancreatic Cancer

June 3rd 2022

Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC

April 13th 2022

The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.

Genetically Adjusting PSA May Improve Screening with PSA Alone in Prostate Cancer

April 11th 2022

The genetic adjustment of prostate-specific antigen could reduce over-diagnosis, de-escalate invasive testing, and improve the detection of aggressive disease in patients with prostate cancer.

NCCN Guidelines: How to Shared Decisions in Metastatic TNBC Treatment

December 17th 2021

As part of its CURE Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about shared-decision making with the NCCN guidelines on metastatic triple-negative breast cancer.

The Impact of the NCCN Guidelines on Metastatic TNBC Treatment

December 17th 2021

CURE discusses the National Comprehensive Cancer Network guidelines and what they mean for patients with metastatic triple-negative breast cancer.

Ibrutinib Plus FCR Shows Encouraging Activity as Time-Limited Option for Younger Patients With CLL

December 13th 2021

The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.